Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

BACKGROUND: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug interactions (DDIs) that could affect the efficacy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Drug Investig
Autores principales: Csonka, Dénes, Bruderer, Shirin, Schultz, Armin, Soergel, Marianne, Stepanova, Radka, Sabattini, Giancarlo, Perez-Ruixo, Juan Jose
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842351/
https://ncbi.nlm.nih.gov/pubmed/31552642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00857-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares